文献速递心境障碍

抗精神病药治疗与难治性抑郁症患者自杀风险:目标试验模拟框架研究

Antipsychotic therapy and suicide risk in patients with treatment-resistant depression: target trial emulation framework study.
PubMed 文献 · Br J Psychiatry · 2025-04-08

该研究纳入2009至2020年间一年内接受两种抗抑郁药治疗的抑郁症患者,采用克隆-删失-加权方法处理时间滞后偏倚,比较抗精神病药增效治疗与第三种抗抑郁药。结果显示,在解决时间滞后偏倚后,抗精神病药增效治疗与自杀未遂或自杀死亡风险降低无关,但与全因死亡率升高相关;作者认为这些发现不支持在难治性抑郁症患者中使用抗精神病药增效治疗。

要点

  • 在解决时间滞后偏倚后,抗精神病药增效治疗与自杀未遂风险无关(HR 1.06;95%CI 0.89-1.29)。
  • 抗精神病药增效治疗与自杀死亡风险无关(HR 1.22;95%CI 0.91-1.71)。
  • 抗精神病药使用者全因死亡风险升高(HR 1.21;95%CI 1.07-1.33)。

核心结论

  • 在解决时间滞后偏倚后,抗精神病药增效治疗与自杀相关结局风险降低无关,但与全因死亡率升高相关;这些发现不支持在难治性抑郁症患者中使用抗精神病药增效治疗。

研究设计与样本

  • 研究纳入2009至2020年间一年内接受两种抗抑郁药治疗的抑郁症患者,采用克隆-删失-加权方法处理时间滞后偏倚,将参与者分配至抗精神病药或第三种抗抑郁药组。
  • 队列包括39949名接受抗精神病药治疗的患者和同样数量的匹配抗抑郁药患者,平均年龄51.2岁(标准差16.0),37.3%为男性。
  • 主要结局为自杀未遂和自杀死亡,心血管死亡和全因死亡作为安全性结局,使用加权合并逻辑回归和非参数自举法估计近似风险比和95%置信区间。

主要发现

  • 与接受第三种抗抑郁药的患者相比,接受抗精神病药的患者自杀未遂风险降低(子分布风险比0.77;95%CI 0.72-0.83),但自杀死亡风险无显著差异(调整风险比1.08;95%CI 0.93-1.27)。
  • 应用克隆-删失-加权方法后,抗精神病药增效治疗与自杀未遂风险降低无关(风险比1.06;95%CI 0.89-1.29),与自杀死亡风险也无关(风险比1.22;95%CI 0.91-1.71)。
  • 然而,抗精神病药使用者全因死亡风险升高(风险比1.21;95%CI 1.07-1.33)。

临床怎么用

  • 原文结论指出,这些发现不支持在难治性抑郁症患者中使用抗精神病药增效治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies investigating the effectiveness of augmentation therapy have been limited. AIMS: To evaluate the effectiveness of antipsychotic augmentation therapies among patients with treatment-resistant depression. METHOD: We included patients diagnosed with depression receiving two antidepressant courses within 1 year between 2009 and 2020 and used the clone-censor-weight approach to address time-lag bias. Participants were assigned to either an antipsychotic or a third-line antidepressant. Primary outcomes were suicide attempt and suicide death. Cardiovascular death and all-cause mortality were considered as safety outcomes. Weighted pooled logistic regression and non-parametric bootstrapping were used to estimate approximate hazard ratios and 95% confidence intervals. RESULTS: The cohort included 39 949 patients receiving antipsychotics and the same number of matched antidepressant patients. The mean age was 51.2 (standard deviation 16.0) years, and 37.3% of participants were male. Compared with patients who received third-line antidepressants, those receiving antipsychotics had reduced risk of suicide attempt (sub-distribution hazard ratio 0.77; 95% CI 0.72-0.83) but not suicide death (adjusted hazard ratio 1.08; 95% CI 0.93-1.27). After applying the clone-censor-weight approach, there was no association between antipsychotic augmentation and reduced risk of suicide attempt (hazard ratio 1.06; 95% CI 0.89-1.29) or suicide death (hazard ratio 1.22; 95% CI 0.91-1.71). However, antipsychotic users had increased risk of all-cause mortality (hazard ratio 1.21; 95% CI 1.07-1.33). CONCLUSIONS: Antipsychotic augmentation was not associated with reduced risk of suicide-related outcomes when time-lag bias was addressed; however, it was associated with increased all-cause mortality. These findings do not support the use of antipsychotic augmentation in patients with treatment-resistant depression.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tsai DH, Yang AS, Wong ZX, et al. Antipsychotic therapy and suicide risk in patients with treatment-resistant depression: target trial emulation framework study. Br J Psychiatry. 2025. PMID: 40197402. doi:10.1192/bjp.2024.283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。